Search research articles
Contact Us
Filters
Showing results (1-10 of 11) with videos related to
Page
of 2
Sort By:
Mathematical Medicine and Biology : a Journal of the IMA
|
March 25, 2017
A stochastic model for tumour control probability that accounts for repair from sublethal damage
Ana Victoria Ponce Bobadilla, Philip K Maini, Helen Byrne
CPT: Pharmacometrics & Systems Pharmacology
|
October 16, 2023
Integrating machine learning with pharmacokinetic models: Benefits of scientific machine learning in adding neural networks components to existing PK models
Diego Valderrama, Ana Victoria Ponce-Bobadilla, Sven Mensing, et al.
CPT: Pharmacometrics & Systems Pharmacology
|
May 9, 2025
Use of Model-Based Meta-Analysis to Inform the Design of Early Clinical Trials of Anti-Amyloid Beta Therapies in Alzheimer's Disease
Sagar S Bachhav, Ana Victoria Ponce-Bobadilla, Diana Clausznitzer, et al.
Clinical and Translational Science
|
October 28, 2024
Practical guide to SHAP analysis: Explaining supervised machine learning model predictions in drug development
Ana Victoria Ponce-Bobadilla, Vanessa Schmitt, Corinna S Maier, et al.
Bulletin of Mathematical Biology
|
June 16, 2019
Age Structure Can Account for Delayed Logistic Proliferation of Scratch Assays
Ana Victoria Ponce Bobadilla, Thomas Carraro, Helen M Byrne, et al.
Clinical Pharmacokinetics
|
December 26, 2022
Upadacitinib Population Pharmacokinetics and Exposure-Response Relationships in Ulcerative Colitis Patients
Ana Victoria Ponce-Bobadilla, Sven Stodtmann, Doerthe Eckert, et al.
Clinical Pharmacology in Drug Development
|
July 2, 2024
SERENE ER Analysis Part 2 SERENE-UC: Exposure-response Analysis of Higher Versus Standard Adalimumab Dosing Regimens for Patients with Moderately to Severely Active Ulcerative Colitis
Sven Stodtmann, Mong-Jen Chen, Ana Victoria Ponce-Bobadilla, et al.
Clinical Pharmacology in Drug Development
|
July 2, 2024
SERENE ER Analysis Part 1-SERENE CD: Exposure-Response Analysis of Higher Versus Standard Adalimumab Dosing Regimens for Patients With Moderately to Severely Active Crohn Disease
Mong-Jen Chen, Ana Victoria Ponce-Bobadilla, Sven Stodtmann, et al.
Journal of the Royal Society, Interface
|
April 9, 2019
In vitro cell migration quantification method for scratch assays
Ana Victoria Ponce Bobadilla, Jazmine Arévalo, Eduard Sarró, et al.
Clinical Pharmacokinetics
|
March 11, 2023
Assessing the Impact of Immunogenicity and Improving Prediction of Trough Concentrations: Population Pharmacokinetic Modeling of Adalimumab in Patients with Crohn's Disease and Ulcerative Colitis
Ana Victoria Ponce-Bobadilla, Sven Stodtmann, Mong-Jen Chen, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 11) with videos related to
Sort By:
Page
of 2
Mathematical Medicine and Biology : a Journal of the IMA
|
March 25, 2017
A stochastic model for tumour control probability that accounts for repair from sublethal damage
Ana Victoria Ponce Bobadilla, Philip K Maini, Helen Byrne
CPT: Pharmacometrics & Systems Pharmacology
|
October 16, 2023
Integrating machine learning with pharmacokinetic models: Benefits of scientific machine learning in adding neural networks components to existing PK models
Diego Valderrama, Ana Victoria Ponce-Bobadilla, Sven Mensing, et al.
CPT: Pharmacometrics & Systems Pharmacology
|
May 9, 2025
Use of Model-Based Meta-Analysis to Inform the Design of Early Clinical Trials of Anti-Amyloid Beta Therapies in Alzheimer's Disease
Sagar S Bachhav, Ana Victoria Ponce-Bobadilla, Diana Clausznitzer, et al.
Clinical and Translational Science
|
October 28, 2024
Practical guide to SHAP analysis: Explaining supervised machine learning model predictions in drug development
Ana Victoria Ponce-Bobadilla, Vanessa Schmitt, Corinna S Maier, et al.
Bulletin of Mathematical Biology
|
June 16, 2019
Age Structure Can Account for Delayed Logistic Proliferation of Scratch Assays
Ana Victoria Ponce Bobadilla, Thomas Carraro, Helen M Byrne, et al.
Clinical Pharmacokinetics
|
December 26, 2022
Upadacitinib Population Pharmacokinetics and Exposure-Response Relationships in Ulcerative Colitis Patients
Ana Victoria Ponce-Bobadilla, Sven Stodtmann, Doerthe Eckert, et al.
Clinical Pharmacology in Drug Development
|
July 2, 2024
SERENE ER Analysis Part 2 SERENE-UC: Exposure-response Analysis of Higher Versus Standard Adalimumab Dosing Regimens for Patients with Moderately to Severely Active Ulcerative Colitis
Sven Stodtmann, Mong-Jen Chen, Ana Victoria Ponce-Bobadilla, et al.
Clinical Pharmacology in Drug Development
|
July 2, 2024
SERENE ER Analysis Part 1-SERENE CD: Exposure-Response Analysis of Higher Versus Standard Adalimumab Dosing Regimens for Patients With Moderately to Severely Active Crohn Disease
Mong-Jen Chen, Ana Victoria Ponce-Bobadilla, Sven Stodtmann, et al.
Journal of the Royal Society, Interface
|
April 9, 2019
In vitro cell migration quantification method for scratch assays
Ana Victoria Ponce Bobadilla, Jazmine Arévalo, Eduard Sarró, et al.
Clinical Pharmacokinetics
|
March 11, 2023
Assessing the Impact of Immunogenicity and Improving Prediction of Trough Concentrations: Population Pharmacokinetic Modeling of Adalimumab in Patients with Crohn's Disease and Ulcerative Colitis
Ana Victoria Ponce-Bobadilla, Sven Stodtmann, Mong-Jen Chen, et al.
Page
of 2